Skip to main content
Clinical Trials/NCT02622997
NCT02622997CompletedNot Applicable

A Study Comparing the Stability for Human Papillomavirus Testing of Three Dry Vaginal Self-samples Taken by Women Attending a Colposcopy Clinic

Queen Mary University of London0 sites60 target enrollmentStarted: July 1, 2015Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
60
Primary Endpoint
Presence of HPV DNA (primarily HPV16) measured by qPCR and the quantity remaining under different storage conditions using dry flocked swabs and HerSwab

Study Overview

Brief Summary

60 women from the Colposcopy Clinic at the Royal London Hospital will be recruited, having been referred following an abnormal cervical screening result.

Aim Human Papillomavirus (HPV) is very common and can cause cervical cancer in some women. There is interest in HPV testing in place of the smear test currently used for cervical screening. HPV testing has potential for women to take self-samples.

These self-samples have up to now mostly been placed into liquid to preserve them before testing. Using liquid however, makes it more difficult to collect samples at home due to spillage and the logistics of posting. Investigators plan to investigate whether dry samples are reliable. Investigators would also like to know if samples can still be used if not tested immediately, particularly in warm temperatures. This would prove useful in the countries that have found it difficult to set up national cervical screening programmes.

Trial Design Investigators are asking women to take three vaginal self-samples before patients' colposcopy examination. The samples will be two swabs and a third using the HerSwab device, designed to make taking a sample easier. Investigators will give women instruction sheets with illustrations. Samples, taken in a random order so that all samples have an equal chance, will be sent to the laboratory for testing but under different conditions. Samples will be either frozen immediately, stored at 25ºC for one week or two weeks and then frozen. All samples will then undergo HPV testing. Investigators wish to see if all conditions and swabs provide similar amounts of HPV.

Enrolment is planned to start in May 2015. Sample processing and testing will continue until enrolment is complete and for a further month. Smear and biopsy results will be collected for up to 6 months to see if they affect quantities of HPV.

Detailed Description

Background Cervical cancer is caused by persistent infection with high risk human papillomavirus types (Hr-HPV) but can be prevented if detected at an early stage. Prevention through routine cervical screening is traditionally done with liquid-based cytology sampling where the cells collected by clinicians are examined to identify abnormal features. Another method is HPV testing performed on the same liquid-based samples as for cytology. HPV DNA testing is more sensitive, but less specific, than cytology for cervical screening and both tests are broadly acceptable to women (Forrest, McCaffery et al. 2004; Waller, McCaffery et al. 2006; Szarewski, Cadman et al. 2009). Although clinician-taken samples are the gold standard, self-sampling may be a useful alternative. HPV DNA testing using self-collected (SC) samples has been shown to have acceptable sensitivity and specificity for HPV testing compared to samples taken by clinicians (Petignat, Faltin et al. 2007; Szarewski, Cadman et al. 2007; Arbyn, Verdoodt et al. 2014). A high level of concordance between self and clinician sample for HPV DNA detection of 0.87 (95% Confidence Intervals (CI), 0.82-0.91) was shown in Petignat's systematic review and meta-analysis (Petignat, Faltin et al. 2007). HPV DNA testing is well established but newer HPV testing technologies are available and emerging.

HPV DNA testing has most commonly been performed on cervical samples collected in a liquid medium (generally Specimen Transport Medium (STM) or PreservCyt). However, this is not ideal for home SC samples because there are often restrictions on postage of biological samples in liquid, risks (although low) pertaining to the transport medium itself and issues around refrigeration of the liquid. The removal of the necessity for a liquid transport medium (and especially any subsequent refrigeration) would greatly improve the accessibility of SC sampling and reduce costs. This would also increase the potential for cervical screening in those areas where there may be logistical difficulties such as lack of regular, frequent postal collections or refrigerated storage facilities.

There have been several studies which have investigated dry sample collection for HPV DNA detection (Shah, Daniel et al. 2001; Krech, Castriciano et al. 2009; Feng, Cherne et al. 2010; Cerigo, Coutlee et al. 2012; Darlin, Borgfeldt et al. 2013; Eperon, Vassilakos et al. 2013). However, the differing methodologies and requirements for refrigeration have restricted the generalisability of the results. They have also not addressed the question of how long the sample on the dry collection device would remain viable, especially under higher temperatures.

Rationale and Risks/Benefits Evidence increasingly suggests that, at least in temperate climates, HPV DNA testing from a SC sample using a dry swab provides similar sensitivity to a wet swab (where the SC sample is placed in liquid specimen transport medium) (Wolfrum, Koutsky et al. 2012). Dry transport could make HPV DNA testing from SC samples more accessible and widely available. In the UK for example, postal packaging is simplified when no liquid is involved. HPV primary screening is being explored in clinical trials and even being introduced into some screening programmes. In the Netherlands for example SC HPV DNA testing within the primary screening programme is planned for introduction for non-attenders in 2016 (Rijksinstituut voor Volksgezondheid en Milieu 2014).

The rationale of this stability study is to ascertain whether SC samples kept under dry conditions will still be useful if left for a period of time in warm conditions. This would be of particular use in the many low and middle income countries where cervical cancer incidence and mortality are highest. These countries have frequently found it very difficult to set up national cervical screening programmes due to lack of infrastructure, access to efficient refrigeration and a postal service.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Screening
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Women attending for colposcopic examination at the Royal London Bart's Health Colposcopy Clinic
  • •Referred as a consequence of abnormal screening cytology
  • •Who have a cervix
  • •Who give written informed consent
  • •Aged 18 years and above

Exclusion Criteria

  • •Any inclusion criteria not met
  • •Pregnant at time of visit
  • •History of excisional or ablative treatment for CIN within the last three years

Arms & Interventions

Flocked swab 1

Experimental

Cervico-vaginal self-sample taken with first flocked swab followed by cervico-vaginal self-sample taken with a second flocked swab and finally cervico-vaginal self-sample taken with a HerSwab device

Intervention: Cervico-vaginal self-sample taken with first flocked swab (Other)

Flocked swab 1

Experimental

Cervico-vaginal self-sample taken with first flocked swab followed by cervico-vaginal self-sample taken with a second flocked swab and finally cervico-vaginal self-sample taken with a HerSwab device

Intervention: Cervico-vaginal self-sample taken with a second flocked swab (Other)

Flocked swab 1

Experimental

Cervico-vaginal self-sample taken with first flocked swab followed by cervico-vaginal self-sample taken with a second flocked swab and finally cervico-vaginal self-sample taken with a HerSwab device

Intervention: Cervico-vaginal self-sample taken with a HerSwab device (Other)

Outcomes

Primary Outcomes

Presence of HPV DNA (primarily HPV16) measured by qPCR and the quantity remaining under different storage conditions using dry flocked swabs and HerSwab

Time Frame: From sample taken at baseline visit

Presence of Human DNA measured by a qPCR assay and the quantity remaining under different storage conditions using dry flocked swabs and HerSwab

Time Frame: From sample taken at baseline visit

RLUs or ct values measured using a validated HPV test on samples under different storage conditions using dry flocked swabs and HerSwab

Time Frame: From sample taken at baseline visit

Secondary Outcomes

  • Primary endpoint 1 analysed by grade of histologically confirmed cervical intraepithelial neoplasia (CIN) or cytology(Up to six months from baseline visit)
  • Primary endpoint 2 analysed by grade of histologically confirmed CIN or cytology(Up to six months from baseline visit)
  • Primary endpoint 3 analysed by grade of histologically confirmed CIN or cytology(Up to six months from baseline visit)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Similar Trials